Conflict of Interest
The authors declare no conflict of interest.

References

1. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020;323(8):707-708.
2. World Health Organization. Coronavirus Disease 2019: Situation Report - 92. 2020.
3. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R, eds. Features, Evaluation and Treatment Coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2020.
4. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020.
5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020.
6. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2).
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497-506.
8. Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). medRvix 2020.02.18.20024364v1; 2020.
9. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020.
10. Peking University First Hospital. Favipiravir Combined with Tocilizumab in the Treatment of Corona Virus Disease 2019. https://ClinicalTrials.gov/show/NCT04310228. 2020.
11. Xu X, Han M, Li T, Sun W, Wang D, Fu B. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv. 202003.00026v1. 2020.
12. Pharmaceuticals R, Sanofi. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19. https://ClinicalTrials.gov/show/NCT04315298. 2020.
13. Zhou L, Xu H. A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia COVID-19. (ChiCTR2000030089): Results pending. 2020.
14. Anger F, Wiegering A, Wagner J, et al. Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report. Rheumatology (Oxford). 2017;56(9):1628-1629.
15. Yuengsrigul A, Chin TW, Nussbaum E. Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. Ann Allergy Asthma Immunol. 1999;83(6):559-566.
16. Lee W-S, Lee S-M, Kim M-K, et al. The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. Int Immunopharmacol. 2013;17(3):721-726.
17. Hardman JG, Goodman LS, Gilman AG, eds. Goodman & Gilman's The pharmacological basis of therapeutics. 10. ed. New York, NY: McGraw-Hill Med. Publ; 2001.
18. Pichette V, Du Souich P. Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. J Am Soc Nephrol. 1996;7(2):345-349.
19. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387-395.
20. Burg M, Stoner L, Cardinal J, Green N. Furosemide effect on isolated perfused tubules. Am J Physiol. 1973;225(1).
21. Berman LB, Ebrahimi A. Experiences with Furosemide in Renal Disease. Proc Soc Exp Biol Med. 1965;118:333-336.
22. Calesnick B, Christensen JA, Richter M. Absorption and excretion of furosemide-S35 in human subjects. Proc Soc Exp Biol Med. 1966;123(1):17-22.
23. Benet LZ. Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm. 1979;7(1):1-27.
24. Jacobson HR, Kokko JP. Diuretics: sites and mechanisms of action. Annu Rev Pharmacol Toxicol. 1976;16(1):201-214.
25. Odlind B, Beermann B. Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther. 1980;27(6):784-790.
26. Bianco S, Robuschi M, Vaghi A, Pasargiklian M. Prevention of Exercise-Induced Bronchoconstriction by Inhled Frusemide. The Lancet. 1988;332(8605):252-255.
27. Prandota J. Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases. Am J Ther. 2002;9(4):317-328.
28. Owens D. Nebulized Furosemide for the Treatment of Dyspnea. J Hosp Palliat Nurs. 2009;11(4):200-201.
29. Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care. 2007;52(7):900-910.
30. Yuengsrigul A, Chin TW, Nussbaum E. Decrease Cytokine Production from Human Peripheral Blood Mononuclear Cells (PBMCs) by Furosemide. Pediatr Res. 1996;39:15.
31. Xu B, Makris A, Thornton C, Ogle R, Horvath JS, Hennessy A. Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy. J Hypertens. 2006;24(5):915-922.
32. Manuscript submitted.
33. University of North Carolina, Chapel Hill, Duke University, Eunice Kennedy Shriver National Institute of Child Health and Human Development, The Emmes Company LLC. Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD). https://ClinicalTrials.gov/show/NCT02527798. 2015.
34. Armed Forces Hospital Pakistan. Role of Salbutamol and Furosemide in TTN. https://ClinicalTrials.gov/show/NCT03208894. 2016.
35. University of Cologne. Trial on Treatment with Inhaled Furosemide of Preterm and Term Neonates with Transient Tachypnoea. https://ClinicalTrials.gov/show/NCT01407848. 2012.
36. McGill University. Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness. https://ClinicalTrials.gov/show/NCT01851980. 2016.
37. Oxford Brookes University. Specificity of Dyspnoea Relief with Inhaled Furosemide. https://ClinicalTrials.gov/show/NCT02881866. 2015.
38. Grogono JC, Butler C, Izadi H, Moosavi SH. Inhaled furosemide for relief of air hunger versus sense of breathing effort: a randomized controlled trial. Respir Res. 2018;19(1):181.
39. Moosavi SH, Binks AP, Lansing RW, Topulos GP, Banzett RB, Schwartzstein RM. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol. 2007;156(1):1-8.
40. Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med. 2000;161(6):1963-1967.
41. Alshehri M, Almegamesi T, Alfrayh A. Efficacy of nebulized furosemide in children with moderate attack of asthma. West Afr J Med. 2005;24(3):246-251.
42. Nuhoğlu C, Yaşar Kiliç M, Ceran O. Effectiveness of nebulized furosemide added to nebulized salbutamol in children with acute asthma. Allergol Immunopathol (Madr). 2006;34(2):54-58.
43. Ono Y, Kondo T, Tanigaki T, Ohta Y. Furosemide given by inhalation ameliorates acute exacerbation of asthma. J Asthma. 1997;34(4):283-289.
44. Pendino JC, Nannini LJ, Chapman KR, Slutsky A, Molfino NA. Effect of inhaled furosemide in acute asthma. J Asthma. 1998;35(1):89-93.
45. Chin T, Franchi L, Nussbaum E. Reversal of bronchial obstruction in children with mild stable asthma by aerosolized furosemide. Pediatr Pulmonol. 1994;18(2):93-98.
46. Banzett RB, Schwartzstein RM, Lansing RW, O'Donnell CR. Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness. Respir Physiol Neurobiol. 2018;247:24-30.
47. Voss TG, Gatti PJ, Fermin CD, Garry RF. Reduction of Human Immunodeficiency Virus Production and Cytopathic Effects. Virology. 1996;219:291-294.
48. Ulug ET, Garry RF, Bose HR. The role of monovalent cation transport in Sindbis virus maturation and release. Virology. 1989;172(1):42-50.
49. Hartley CE, Buchan A, Randall S, Skinner GR, Osborne M, Tomkins LM. The effects of lithium and potassium on macromolecular synthesis in herpes simplex virus-infected cells. J Gen Virol. 1993;74 (Pt 8):1519-1525.
50. Hartley C, Hartley M, Pardoe I, Knight A. Ionic Contra-Viral Therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch Virol. 2006;151(12):2495-2501.
51. Rijsbergen M, Niemeyer-van der Kolk T, Hogendoorn G, et al. A randomized controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts. Br J Dermatol. 2019;180(5):1058-1068.
52. Hung C-M, Peng C-K, Wu C-P, Huang K-L. Bumetanide attenuates acute lung injury by suppressing macrophage activation. Biochem Pharmacol. 2018;156:60-67.
53. Lan C-C, Peng C-K, Tang S-E, et al. Inhibition of Na-K-Cl cotransporter isoform 1 reduces lung injury induced by ischemia-reperfusion. J Thorac Cardiovasc Surg. 2017;153(1):206-215.
54. O'Connor BJ, Chung KF, Chen-Worsdell YM, Fuller RW, Barnes PJ. Effect of inhaled furosemide and bumetanide on adenosine 5'-monophosphate- and sodium metabisulfite-induced bronchoconstriction in asthmatic subjects. Am Rev Respir Dis. 1991;143(6):1329-1333.
55. Yeo CT, O'Connor BJ, Chen-Worsdell M, Barnes PJ, Chung KF. Protective effect of loop diuretics, piretanide and frusemide, against sodium metabisulphite-induced bronchoconstriction in asthma. Eur Respir J. 1992;(5):1184-1188.
56. Bianco S, Robuschi M, Vaghi A, Pieroni MG, Sestini P. Protective effect of inhaled piretanide on the bronchial obstructive response to ultrasonically nebulized H2O. A dose-response study. Chest. 1993;104(1):185-188.
57. Hampel P, Römermann K, MacAulay N, Löscher W. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B. Sci Rep. 2018;8(1):9877.
58. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest. 2008;133(6):1388-1396.
59. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med. 1999;159(6):1843-1848.
60. Nijs SB de, Fens N, Lutter R, et al. Airway inflammation and mannitol challenge test in COPD. Respir Res. 2011;12:11.
61. Chen D, Li X, Song Q, Hu C, Su F, Dai J. Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19): medRxiv 2020.02.27.20028530v1; 2020.
62. Lippi G, South AM, Henry BM. ANNALS EXPRESS: Electrolyte Imbalances in Patients with Severe Coronavirus Disease 2019 (COVID-19). Ann Clin Biochem. 2020:4563220922255.
63. Greenblatt DJ, Duhme DW, Allen MD, Koch-Weser J. Clinical toxicity of furosemide in hospitalized patients. Am Heart J. 1977;94(1):6-13.
64. Waskiw-Ford M, Wu A, Mainra A, et al. Effect of Inhaled Nebulized Furosemide (40 and 120 mg) on Breathlessness during Exercise in the Presence of External Thoracic Restriction in Healthy Men. Front Physiol. 2018;9:86.
65. Stone P, Rix, Kurowska A, Tookman. Re: nebulized furosemide for dyspnea in terminal cancer patients. J Pain Symptom Manag. 2002;24(3):274-275.
66. Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet. 2020.